Skip to main content

Advertisement

Table 4 Secondary outcome measures

From: Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey

  Total FF MF FP
  N Mean (SD) N Mean (SD) N β CI N β CI
PSQI Overall 370 4.25 (3.00) 183 4.14 (3.14) 87 0.34 −0.37 to 1.06 100 0.08 −0.60 to 0.77
WPAI % work time missed due to allergy 258 1.66 (9.57) 133 2.23 (12.57) 62 −1.31 −4.23 to 1.61 63 −1.10 −4.02 to 1.82
WPAI % impairment while working due to allergy 273 18.06 (16.55) 143 16.99 (16.79) 65 1.33 −3.53 to 6.20 65 3.09 −1.80 to 7.98
WPAI % overall work impairment due to allergy 255 18.93 (18.27) 131 17.88 (19.29) 62 1.67 −3.86 to 7.21 62 2.43 −3.13 to 7.98
WPAI % class time missed due to allergy 55 1.97 (5.99) 27 1.36 (4.09) 16 1.30 −2.80 to 5.40 12 −1.14 −5.98 to 3.70
WPAI % impairment in the classroom due to allergy 61 17.05 (17.16) 31 16.77 (18.51) 16 −5.33 −15.89 to 5.24 14 −0.81 −12.91 to 11.28
WPAI % overall classroom impairment due to allergy 55 17.37 (17.73) 27 16.44 (17.96) 16 −2.96 −14.69 to 8.76 12 1.02 −12.83 to 14.87
WPAI % activity impairment due to allergy 425 20.16 (16.86) 215 18.42 (16.95) 100 3.20 −0.77 to 7.16 110 3.24 −0.62 to 7.09
Number of work days lost in the previous 3 months due to AR 297 0.78 (3.12) 151 0.59 (1.75) 70 0.55 −0.36 to 1.45 76 0.37 −0.51 to 1.25
Number of PCP visits, as reported by patient, in the previous 3 months 436 2.06 (1.72) 220 1.95 (1.36) 102 0.13 −0.27 to 0.53 114 0.23 −0.16 to 0.62
Number of specialist visits as reported by patient, in the previous 3 months 437 0.96 (1.37) 220 0.88 (1.24) 103 0.15 −0.16 to 0.47 114 0.09 −0.21 to 0.40
Number of PCP visits, as reported by physician, in the previous 3 months 283 2.22 (1.04) 144 2.19 (0.98) 66 0.09 −0.21 to 0.38 73 −0.12 −0.40 to 0.17
Number of specialist visits as reported by physician, in the previous 3 months 153 2.28 (1.32) 76 2.16 (1.18) 36 0.37 −0.13 to 0.87 41 0.17 −0.30 to 0.65
Number of non-prescribed (OTC) drugs over the previous 4 weeks 437 0.24 (0.53) 220 0.19 (0.45) 103 0.05 −0.06 to 0.19 114 0.12 0.01 to 0.23*
  1. FF: Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone furoate; β = adjusted mean difference from FF.
  2. *p<0.05 (Bonferroni correction applied).